Currently available antiepileptic drugs such as carbamazepine, phenobarbital, phenytoin, and primidone are effective in controlling epileptic seizures in many patients. However, there remains a large group of people for whom seizures cannot be controlled with drugs. In adults, the partial seizures (simple partial, complex partial, and partial seizures evolving to generalized seizures) are among the most difficult to control with medical management. There is a need to develop and test new compounds that may be safe and effective in the treatment of partial seizures.
There is evidence that a new compound, zonisamide (1,2-benzisoxazole-3-methanesulfonamide), may be an effective antiepileptic drug. The anticonvulsant properties of zonisamide were discovered through extensive testing of numerous 3-substituted 1,2-benzisoxazole compounds (Masuda et al., 1980) . These properties of zonisamide were demonstrated in several animal models, including maximal electroshock seizures, maximal pentylenetetrazole-induced seizures, and kindling (Masuda et al., 1979 (Masuda et al., , 1980 Kamei et al., 1981) . The compound has been shown to suppress focal spiking and spread of secondarily generalized seizures in experimental animals (Ito et al., 1980) . These studies indicate that the anticonvulsant profile of zonisamide is similar to that of phenytoin or carbamazepi-ne (Masuda et al., 1980; Kamei et al., 1981) . Masuda et al. (1979) studied the relationship of plasma concentrations of zonisamide, its anticonvulsant effects, and impaired motor function in several species. Based on comparisons with phenytoin, phenobarbital, and carbamazepine in these animal paradigms, the authors predicted that zonisamide would be effective clinically in plasma concentrations between 10 and 70 p,g/ml.
The present protocol was designed to study the singleand multiple-dose pharmacokinetics of zonisamide in patients receiving other antiepileptic drugs, to evaluate the safety of zonisamide with chronic administration, and to provide preliminary evidence of the efficacy of zonisamide in controlling medically refractory partial seizures in humans.
PATIENTS AND METHODS
Six men and five women of nonchildbearing potential entered the study. All patients were between 19 and 50 years of age and had at least four partial seizures per month, in spite of therapeutic plasma levels of two or (Dreifuss et al., 1981) . One patient withdrew from the study in the baseline period, before receiving zonisamide. The study protocol is outlined in Table 1 .
Baseline
The protocol included an 8-week baseline period during which each patient continued receiving either two or three standard antiepileptic drugs. The baseline treatment for each patient had previously been determined, on clinical grounds, to be the most effective regimen for that individual. The baseline treatment for each patient is listed in Table 2 . Patients kept daily seizure logs throughout the study and were evaluated every 4 weeks during the baseline period. This evaluation included a review of the seizure log, interval medical history, general physical and neurological examinations, electrocardiogram, EEG, complete blood count, blood chemistry profile, measurement of plasma anticonvulsant drug levels, and urinalyses. A neuropsychological test battery was performed at the end of the baseline period.
Single-dose pharmacokinetic study
Following the baseline period, a single-dose kinetic study was performed. A single oral dose of zonisamide was given on the first day. Blood samples were obtained at 0, 0.33, 0.67, 1, 2, 4, 8, 12, 24, 36, 48, 60, 72, 84 , and 96 h. These samples were assayed to determine the plasma and whole blood concentrations of zonisamide, using a high-pressure liquid chromatography technique (Warner-Lambert). Red blood cell concentrations were calculated from the plasma and whole blood concentrations and the hematocrit. Formulas used for calculating kinetic parameters are given in the Appendix.
Multiple-dose pharmacokinetic study
After completion of the single-dose kinetic phase, zonisamide was administered orally every 12 h. The dose for each patient was based on estimation of pharmacokinetic parameters derived from the single-dose kinetic study. An oral clearance rate was calculated for each patient (see Appendix for formulas). Then, based on a linear kinetic model, the dose required to achieve an average steady-state concentration of 17.5 pg/ml was calculated. The actual dose given in each case was -80% of the calculated dose. This dose was given daily in two divided doses (every 12 h) for 7 days. During this interval, trough blood samples were taken every 48 h for measurement of whole blood and plasma levels.
Withdrawal of one baseline drug
On the eighth treatment day, each patient was admitted to the University of Michigan Clinical Research Center for -10 days. One baseline antiepileptic drug was withdrawn, and trough (8 a.m.) plasma levels of all antiepileptic drugs were sampled each day. Approximated peak levels (11 a.m.) were sampled every other day. Doses of zonisamide were adjusted to achieve a plasma level of 15-40 &ml or reduced to eliminate side effects.
Outpatient treatment period
Once the plasma level of the drug withdrawn fell below 15% of the initial level, the patient was discharged from the hospital and evaluated weekly for 4 weeks, and then every 2 weeks for the remainder of the 12-week treatment period. Evaluation procedures were identical to those done during the baseline period. Neuropsychological tests were administered on week 12 of treatment.
RESULTS

Pharmacokinetics of zonisamide
The mean concentrations of zonisamide in plasma, whole blood, and red blood cells, following a single oral dose of 400 mg, are shown in Figure 1 . The mean time to reach peak concentration (t,,,) following a single oral dose of 400 mg was 2.8 h [coefficient of variation (CV) 37%] for plasma and 5.8 (CV 46%) for whole blood. The mean maximum concentration was 5.48 pg/ml (CV J . C . SACKELLARES ET AL.. OWithdrawn during treatment period 'Derived from primidone. 35.6%) for plasma and 13.4 pg/ml (CV 27.3%) for whole blood. The mean plasma clearance was 2.34 L/h (CV 36.6%). The mean plasma elimination rate constant was 0.0264 h-' (CV 26.9%). The calculated half-life was 28.4 h (CV 33.9%). Although maintenance doses were chosen to reach a mean steady-state plasma concentration of 17.5 pg/ml, the actual steady-state levels tended to exceed the predicted value. The actual doses given every 12 h and the resultant average minimum steady-state concentrations in plasma are given in Table  3 . In most cases, the minimum steady-state plasma concentration (Css, -) could be roughly estimated ( & 28%) from the single-dose data using a simple formula: Css,min = 1.81 R/CL, where CL is the plasma clearance and R is the daily dose. However, detailed analysis indicates that zonisamide follows Michaelis-Menten kinetics (Wagner et al., 1984) .
Drug-drug interactions
The doses and plasma concentrations of concomitantly administered antiepileptic drugs are summarized in Table 2. For most drugs, the average plasma concentration during the baseline period was somewhat lower than the average concentration during treatment with zonisamide. There was a consistent rise in average carbamazepine concentrations following initiation of zonisamide therapy.
Seizure control
The effects on seizure control were measured in most cases by comparing the number of seizures during the 8-week baseline period to the number of seizures during the last 8 weeks of treatment (following substitution of zonisamide for one standard antiepileptic drug). These data are summarized in Table 4 . Patient 5 was withdrawn from the study after 3 weeks because of a flurry of seizures. In retrospect, this flurry did not result from treatment with zonisamide, because similar flurries had occurred before the study and continued to occur following discontinuation of administration of the drug. In this case, seizure frequency (number of seizures per week) was used to calculate the percentage change in seizures. Patient 10 did not provide an accurate report of seizures during the first 4 weeks of baseline; in this case, the last 4 weeks of baseline were compared with the last 4 weeks of the treatment period. One patient experienced complete seizure control following treatment with zonisamide. Four others had >75% improvement. All but one of the remaining five patients had at least 50% reduction in seizure frequency. Patient 6 had no change in seizure frequency but reported a reduction in seizure severity. Frequencies of simple partial and complex partial seizures were reduced in most patients. However, generalized seizures occurred slightly more often during the treatment period in two patients.
Side effects and toxicity
All observed or reported side effects are listed in Table  5 . No hematologic, hepatic, renal, cardiac, or other systemic toxic effects were observed. Side effects were observed or reported by all patients, but these were reversible or reduced to a tolerable level in each case. In no case did side effects necessitate withdrawal from the study. The most common side effects were weight loss, nystagmus, mild ataxia, drowsiness, and mild mental confusion. In one patient who exhibited paranoid ideation and withdrawn behavior, zonisamide was withdrawn briefly, and these problems resolved. However, the behavior did not occur following reinstitution of the drug, and she continued taking the drug without side effects. Although symptoms and signs of toxicity appeared to occur primarily when plasma concentrations exceeded 40 pg/ml, a clearly definable toxic plasma level could not be determined in this small number of patients. However, impaired performance on some of the formal measures of cognitive and psychomotor tasks appeared to be related to the plasma levels of zonisamide. The relationship between plasma levels and neuropsychological performance will be discussed in a subsequent publication.
Side effects were most frequent during the initial 2 weeks of treatment with zonisamide. In some cases, side effects were associated with a rise in the plasma level of carbamazepine (three cases) or phenytoin (one case) and were resolved or markedly reduced after the dose of that drug was lowered. In seven patients, side effects were resolved or markedly improved after the dose of zonisamide was reduced. The final maintenance dose, resulting in minimal or no side effects, ranged between 5.2 and 12.5 mg/kg/day (mean * SD 8.5 -1-2.5). The resultant plasma level ranged from 16.5 to 49.6 pg/ml (mean _+ SD 30.7 f 10.2).
DISCUSSION
The results of this study suggest that zonisamide may seizures was reduced after substitution of zonisamide for one of the baseline antiepileptic drugs. This observation must be interpreted cautiously. In an unblinded study with no control group, the possibilities of observer bias or placebo effects must be considered. It is conceivable that elimination of one of the baseline antiepileptic drugs could have improved seizure control. However, these preliminary observations indicate that a more definitive efficacy study, using a double-blind controlled protocol, is warranted. Clinically significant antiepileptic effects were observed with plasma levels between 16.5 and 49.6 pg/ml. Dose-related side effects in the central nervous and gastrointestinal systems were observed. These observations suggest that the therapeutic range predicted from animal studies, 10-70 pg/ml (Masuda et al., 1979) , may represent a reasonable estimate, although toxicity may occur at levels well below 70 pg/ml. Further study will be required to achieve a more accurate estimation of the therapeutic range. Zonisamide is quickly absorbed from the gastrointestinal tract, having an average t,,, of 2.8 h. The calculated average half-life in plasma is -28 h. However, this value may not be meaningful if, as we suspect, the drug follows concentration-dependent kinetics (Wagner et al., 1984) .
The single-dose pharmacokinetic parameters observed in these patients were different from those reported in normal human volunteers by Ito et al. (1982) . In that study, a single oral dose of 400 mg resulted in a mean peak plasma concentration of 13.4 p.g/ml, a mean t,,, of 5.3 h, and a mean elimination half-life of 56.7 h. These differences suggest the possibility of drug-drug interactions affecting the pharmacokinetics of zonisamide in patients receiving other antiepileptic drugs. The observed rise in level of concomitantly administered antiepileptic drugs, particularly carbamazepine, suggests the possibility that zonisamide may alter the pharmacokinetics of other drugs.
The clearance from the plasma following a single oral dose provides a rough prediction of the doses required to achieve a given steady-state concentration. Doses between 4 and 10 mg/kg/day should result in plasma levels in the expected therapeutic range. Zonisamide is highly bound to the red blood cell, resulting in high whole blood concentrations relative to plasma concentrations. The pharmacological and clinical implications of this red blood cell binding require further study. Zonisamide holds promise as a clinically useful antiepileptic drug. Further, more definitive efficacy studies and long-term safety and efficacy studies are in progress.
APPENDIX
be effective in controlling simple partial and complex partial seizures. In all but one case, the number of partial
The following equations were used to calculate pharmacokinetic parameters:
Epilepsia, Vol. 26, NO. 3, 198s In Cp = 1nC; -pt (applied to log-linear postpeak C , and t data) Note that after a 400-mg single dose, kinetics were essentially linear, and linearity was observed when postpeak C, was plotted on semilogarithmic graph paper versus time. Hence, estimation of CL,, V,, and p were perfectly valid.
When the patients were dosed to steady state, the plasma levels increased to a sufficient magnitude that kinetics became nonlinear, and steady-state clearance averaged only -40% of single-dose CL,.
RESUME
Un nouveau produit anticonvulsivant, le zonisamide (1,2 benzisoxazole-methylsulfonamide) a ett administri a 10 adultes atteints de crises partielles non contr6lCes par le traitement mCdical. Apr6s une dose unique orale de 400 mg, le pic du taux plasmatique survient en moyenne 2 h 1/2 aprks l'ingestion, et la clairance plasmatique 
RESUMEN
En 10 adultos con ataques parciales refractarios a1 tratamiento m6d-ico, se ha estudiado la accidn de un nuevo compuesto anticonvulsivo, la zonisamida (1,2 benzisoxazol-metanosulfonamida). Tras la ingestidn de una sola dosis oral de 400 mg., se alcanzaron 10s niveles pic0 en plasma en un promedio de 2.8 horas desputs de la dosis y el aclaramiento medio del plasma fu6 de 2,34 litros/hora. Las concentraciones en sangre fueron mas altas que las plasmaticas debido a que la medicacidn se ligaba a 10s hematies. Las concentraciones plasmaticas estables fueron mis altas que las previsibles de un modelo cinttico lineal. En la mayorfa de 10s pacientes la frecuencia de 10s ataques se redujo despuks de cambiar la medicacidn antiepilbptica standard por la zonisamida. Tambitn se observaron 10s efectos colaterales sobre el tracto gastrointestinal y el sistema nervioso central que estaban relacionadas con la dosis y eran reversibles. La mayor parte de 10s pacientes tolero dosis que oscilaban entre 5.2 y 12.5 mglkgldia.
(A. Portera Sanchez. Madrid) 
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